levels were significantly associated with higher systolic (p = 0.01), diastolic (p = 0.02), and mean (p = 0.01) PAP and possibly higher PVR (p = 0.09). There were no significant associations between VEGF levels and hemodynamics. Conclusions: Higher levels of ET-1 were associated with higher PAP and possibly higher PVR in participants with IPF. In a subgroup of patients, ET-1 may be a contributor to pulmonary vascular disease burden in IPF.
Introduction
Pulmonary hypertension (PH) is a common complication of idiopathic pulmonary fibrosis (IPF) that is associated with a high mortality rate when present [1] [2] [3] [4] [5] [6] [7] . While most individuals with IPF experience mild to moderate elevations in pulmonary artery pressures (PAP), the development (and severity) of PH is not associated with the severity of lung function impairment [2, 4, 5] . It has been postulated that PH in IPF is mediated in large part by hypoxic pulmonary vasoconstriction, but this is unlikely to be the sole determinant of pulmonary vascular disease, given the lack of a clear relationship between lung function and PH [2, 4, 5] .
Endothelin-1 (ET-1) is a potent vasoconstrictor and promoter of pulmonary arterial smooth muscle cell growth with a pivotal role in pulmonary arterial hypertension (PAH) [8] [9] [10] . Elevated levels of ET-1 have been demonstrated in the peripheral and pulmonary circulations of patients with PAH and secondary PH [8, [11] [12] [13] [14] [15] . In addition to its impact on the pulmonary endothelium, ET-1 has mitogenic effects that might contribute to the pathogenesis of pulmonary fibrosis [16] [17] [18] [19] [20] [21] [22] [23] . Adults with interstitial lung disease (ILD) have been shown to have elevated circulating ET-1 levels; however, few studies have examined the association of ET-1 with pulmonary vascular disease in IPF [24] [25] [26] .
As with ET-1, vascular endothelial growth factor (VEGF) is an important mediator in the development of PAH and may play a role in the pathogenesis of IPF (and IPF with PH) [27] [28] [29] . In animal models of IPF, VEGF appears to modulate both fibrosis and endothelial function although its effects are somewhat controversial [29] [30] [31] [32] . VEGF levels may correlate with lung function in IPF patients, but to our knowledge the relationship between VEGF levels and hemodyamics has not been studied [26, 33] .
We examined the cross-sectional associations between plasma ET-1 and VEGF levels and hemodynamics, specifically PAP and pulmonary vascular resistance (PVR), in a cohort of patients with IPF. We hypothesized that higher levels of ET-1 and VEGF would be associated with higher PAP and PVR. [34] . Patients with clinical evidence of collagen vascular disease and lung disease due to environmental or drug exposure were excluded. Patients referred to the ILD and Lung Transplantation Programs undergo transthoracic echocardiograms as part of their routine work-up. Patients with a suggestion of PH (estimated systolic PAP 1 40 mm Hg or evidence of right ventricular dysfunction when an adequate tricuspid regurgitant jet is not seen) and those being considered for lung transplantation go on to have hemodynamics performed. Demographic and clinical data were collected by research staff. Additional physiologic data including pulmonary function testing and 6-min walk distance (6MWD) were performed according to standard clinical protocols [35, 36] . The study was approved by the Columbia University Medical Center Institutional Review Board.
Methods and Materials

Study Design
We included patients with available hemodynamics and banked plasma. We excluded those with hemodynamics and blood draw that were more than 6 months apart, and those without available echocardiography to confirm the absence of left ventricular systolic dysfunction (ejection fraction ! 50%) and/or more than moderate aortic or mitral valve disease.
Hemodynamics
Right heart catheterizations were performed at the Cardiac Catheterization Laboratory of New York Presbyterian Hospital using standard clinical procedures. All catheter tracings were reviewed by two primary investigators (C.E.V., D.J.L.); patients were excluded if pulmonary capillary wedge pressure (PCWP) was determined to be 6 15 mm Hg by either investigator.
Biomarkers
Platelet-free plasma by venipuncture for each participant was collected by a trained phlebotomist, processed, and stored at -80 ° C. Plasma ET-1 and VEGF were measured by quantitative sandwich enzyme immunoassays (QuantiGlo, R&D Systems, Inc, Minneapolis, Minn., USA) at the Laboratory for Clinical Biochemical Research, University of Vermont. Reported manufacturer intra-assay coefficients of variation are between 2.6-3.4 and 2.8-7.9% and interassay coefficients of variation are between 4.6-8.9 and 4.2-8.8% for ET-1 and VEGF, respectively.
Statistical Analysis
Continuous variables were expressed as means and standard deviations. Categorical variables were expressed as percentages. Independent sample t tests were used to compare continuous variables and 2 or Fisher's exact tests were used to compare categorical variables in study participants and those excluded. As they are not normally distributed, ET-1 and VEGF were natural logarithmically transformed. Generalized additive modeling was used to assess the relationship between continuous ET-1 and VEGF levels and hemodynamics. Models were adjusted for age, gender, race/ethnicity, and forced vital capacity (FVC) (percent predicted). Statistical significance was defined as p ! 0.05. Analyses were performed using STATA 10.0 (StataCorp., College Station, Tex., USA).
Results
A total of 129 patients were enrolled in the IPF cohort during the study period ( fig. 1 ). Of these, 74 (57%) had clinical data and right heart catheterization with available catheter tracings at the time of the study. We excluded 10 (14%) with PCWP 6 15 mm Hg, 3 (4%) without available echocardiograms, and 9 (12%) patients whose blood draw and right heart catheterization were performed more than 6 months apart. A total of 52 participants were included in the study. Characteristics of the study sample and those excluded (n = 77) are shown in table 1 . Participants were more likely to be male, to have had systemic hypertension, to have received corti-costeroids, and had more pronounced impairments in lung function and functional class than those excluded. Among participants, the mean age was 63 8 6 years, 83% were male, 94% were non-Hispanic white, and 61% were former smokers. None were receiving targeted PH therapy, such as endothelial receptor antagonists or phosphodiesterase-5 inhibitors. Mean FVC was 56 8 15% predicted, mean 6MWD was 407 8 126 m, and most participants were classified as New York Heart Association (NYHA) functional class II or III. The average time between blood draw and hemodynamic assessment was 60 8 49 days. Forty (77%) of the sample had study measurements performed less than 3 months apart.
The mean ET-1 level was 2.1 8 0.6 pg/ml and the mean VEGF level was 54.9 8 25.5 pg/ml. The mean right atrial pressure was 3. ( table 1 ) . Sixteen of 52 (30.8%) had PH (mean PAP 6 25 mm Hg). Among those with PH, the mean ET-1 level was 2.3 8 0.6 pg/ml and the mean VEGF level was 55.5 8 25.9 pg/ml, as compared to 2.1 8 0.6 pg/ ml and 54.6 8 25.6 pg/ml, respectively, in those without PH.
The continuous relationship between ET-1 levels and hemodynamics are depicted in figure 2 . After adjustment for age, gender, race/ethnicity, and percent predicted FVC, there was a blunted J-shaped relationship between ET-1 levels and systolic PAP (p for nonlinearity = 0.01), diastolic PAP (p for nonlinearity = 0.02), mean PAP (p for nonlinearity = 0.01), and possibly PVR (p for nonlinearity = 0.09). There was no association between ET-1 levels and PAP, PCWP, or cardiac index. There were no significant associations between VEGF levels and hemodynamics (online suppl. fig. E1 , for all online suppl. material, see www.karger.com/doi/10.1159/000339105). Results were unchanged when adjusted for diffusing capacity of the lung for carbon monoxide (DL CO ) (data not shown). ET-1 and VEGF levels were not associated with FVC, DL CO , 6MWD, or NYHA functional class (data not shown). 
Discussion
We have shown that higher plasma ET-1 levels are associated with higher PAP and perhaps PVR in a cohort of patients with IPF after adjustment for demographics and lung function. This relationship is nonlinear and Jshaped, with only a subgroup of patients demonstrating correlations between higher levels of ET-1 and higher PAPs. Conversely, there were no significant associations between VEGF levels and hemodynamics. To our knowl- edge, this is the largest observational study of these circulating biomarkers in IPF.
Several small studies have previously shown elevated levels of ET-1 in patients with ILD (but not necessarily IPF) and that ET-1 levels correlate with mean PAP [25, [37] [38] [39] . Trakada et al. [38] demonstrated that ET-1 concentrations were higher among those with ILD and concurrent PH compared to those without PH in 38 patients. In IPF specifically, the relationship with hemodynamics has not been studied, but ET-1 has been shown to be elevated peripherally and to be overexpressed in the lung [24] . ET-1 appears to localize to small vessel endothelial cells but diffuse into surrounding tissue, suggesting that in certain individuals activation of the ET-1 pathway may lead to uncontrolled fibrosis and perhaps widespread endothelial dysfunction via paracrine effects, resulting in IPF with PH [21, 24, 40, 41] . Randomized clinical trials have studied the effect of endothelial receptor antagonists on disease progression in IPF and IPF with PH (clinicaltrials.gov registry numbers NCT00879229 and NCT00768300) [42, 43] . While the results of these trials have been somewhat disappointing, it is possible that a subgroup of patients with IPF (e.g. those with a particularly active endothelin pathway and therefore a large pulmonary vascular disease burden) may benefit from targeted PH therapy [44] . In fact, while most participants in our study clustered around mid-range ET-1 levels and had mild to modest elevations in PAP and PVR, a small group had strong linear associations between ET-1 and hemodynamics (as shown in fig. 2 ).
In PH and PAH, endothelial VEGF and VEGF receptor production is upregulated in response to vascular insult [27, 28, 45, 46] . Evidence in humans is limited, but VEGF may also modulate angiogenesis and fibrosis in IPF [26, 33] . While some studies have shown VEGF inhibition attenuates pulmonary fibrosis, areas of spared lung appear to have increased vascular density and VEGF upregulation [29] [30] [31] . Farkas et al. [32] demonstrated reduced VEGF expression in fibrotic lung, an inverse correlation of VEGF levels with PAP, and improved endothelial apoptosis, vascular remodeling, and PH with VEGF augmentation, suggesting that decreased vascularity may underpin the development of PH in IPF. While patients with IPF seem to have similar serum levels of VEGF compared with controls, in patients with severe disease there is a significant correlation between VEGF levels and progression of disease [26, 33] . These studies do not separately identify patients with concurrent PH, and our study suggests VEGF may not be a useful biomarker in IPF. The relationship between VEGF, angiogenesis/fibrosis and PH remains poorly described in humans.
Our study has several limitations. First, while the majority had blood draw and hemodynamics measured over a short interval (58% within 8 weeks and 39% within 4 weeks), ideally these would have been performed simultaneously and this may have introduced confounding. No patients were hospitalized between tests, implying relative clinical stability of the cohort. Second, patients were selected for hemodynamic evaluation based on screening echocardiography (or as part of lung transplantation evaluation) and therefore those included in the study tended to be sicker (e.g. had more impaired lung function) than those excluded, possibly resulting in bias. Third, as this is a cross-sectional study, no conclusions can be drawn about causality, i.e. whether elevated ET-1 precedes the development of PH complicating IPF or is simply a marker of pulmonary vascular disease burden. As is commonly seen in IPF, our study sample was predominantly white men, limiting the generalizability of these findings to women and individuals of other races. Last, because of the small number of patients with significant pulmonary vascular disease (31% with mean PAP 6 25 mm Hg), we were underpowered to assess whether ET-1 may be useful to predict PH.
We have shown that higher ET-1 levels are associated with higher PAP and may be associated with higher PVR. Studies will be needed to evaluate ET-1 as a diagnostic screening tool for IPF with PH, and it remains to be seen whether subsets of individuals may benefit from targeted PH therapy.
